IRIDEX Announces Appointment of Robert Gunst as Chairman of the Board of Directors and Departure of Lead Independent Director...
October 28 2019 - 4:05PM
IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment
of Robert Gunst as Chairman of the Board, effective October 23,
2019. Concurrent with this appointment, Ruediger Naumann-Etienne
departed from the Board of Directors as Lead Independent Director.
“On behalf of our Board of Directors, I would like to thank Rudi
for his decade of valuable service and dedication to IRIDEX. We
appreciate his impactful contributions throughout the growth and
transition of our business and wish him all the best in the
future," said David I. Bruce, President and CEO.
Bruce added, “We were delighted to welcome Bob to our Board in
July, and now look forward to his expanded leadership role as our
chairman. His extensive management and corporate governance
experience provides IRIDEX with an important layer of oversight
that will benefit the implementation of our new strategic
direction.”
Mr. Gunst served on the Board of Directors of Natus Medical from
June 2004 to June 2019, acting as its chairman from September 2004
until July 2018. Currently a private investor, Mr. Gunst was
previously President and Chief Executive Officer of The Good Guys,
Inc. Earlier in his career, he held executive positions at
several large corporations, including Shaklee Corporation, PepsiCo
Inc. divisions La Petite Boulangerie, Inc. and PepsiCo Foods (Frito
Lay) International, Victoria Station Incorporated, and The First
National Bank of Chicago. Mr. Gunst has served on a variety of
public and private boards, including as a Director of The Good
Guys, Inc., Phoenix Footwear Group, Inc., PortalPlayer, Inc., AmNet
Mortgage, Inc., and as Chairman of Garden Fresh Restaurant Corp. He
also served as a member of the Deans Advisory Council of the
Graduate School of Management at the University of California,
Davis from 1997 to 2008. Mr. Gunst holds an MBA in Finance from the
University of Chicago’s Graduate School of Business and an A.B. in
Economics from Dartmouth College.
About IRIDEXIRIDEX is a worldwide leader in
developing innovative and versatile laser-based medical systems,
delivery devices and consumable instrumentation for the
ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema (DME) and other
retinal diseases. IRIDEX products are sold in the United
States and Germany through a direct sales force and in more than
100 countries through a network of independent distributors. For
more information, visit http://www.iridex.com.
Investor Relations Contact: Leigh Salvo (415)
937-5404 investors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Sep 2023 to Sep 2024